|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1990
|
|
gptkbp:brand
|
gptkb:Carbatrol
|
|
gptkbp:category
|
gptkb:D
|
|
gptkbp:class
|
gptkb:Antihero
|
|
gptkbp:clinical_trial
|
conducted
|
|
gptkbp:clinical_use
|
gptkb:common
|
|
gptkbp:condition
|
bipolar disorder
trigeminal neuralgia
|
|
gptkbp:contraindication
|
bone marrow suppression
hypersensitivity to carbamazepine
history of aplastic anemia
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:drug_interactions
|
numerous
|
|
gptkbp:duration
|
varies by patient
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:formulation
|
extended-release capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Carbatrol
|
|
gptkbp:ingredients
|
gptkb:carbamazepine
|
|
gptkbp:interacts_with
|
gptkb:warfarin
oral contraceptives
MAO inhibitors
|
|
gptkbp:is_monitored_by
|
gptkb:CBC
liver function tests
|
|
gptkbp:lifespan
|
12 to 17 hours
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Carbatrol
|
|
gptkbp:mechanism_of_action
|
sodium channel blocker
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_education
|
important
|
|
gptkbp:pharmacokinetics
|
variable
|
|
gptkbp:previous_name
|
gptkb:carbamazepine
|
|
gptkbp:provides_guidance_on
|
available
|
|
gptkbp:requires
|
available
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
available
|
|
gptkbp:side_effect
|
dizziness
nausea
liver toxicity
rash
drowsiness
blurred vision
blood disorders
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:strength
|
100 mg
200 mg
300 mg
|
|
gptkbp:symptoms
|
possible
|
|
gptkbp:titration
|
recommended
|
|
gptkbp:type_of_care
|
important
|
|
gptkbp:used_for
|
treating epilepsy
|
|
gptkbp:bfsParent
|
gptkb:carbamazepine
|
|
gptkbp:bfsLayer
|
5
|